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Abstract This article discusses the prospects and limi-
tations of the scientific basis for offering personalized
nutrition advice based upon individual genetic information.
Two divergent scientific positions are presented, with an
ethical comment. The crucial question is whether the cur-
rent knowledge base is sufficiently strong for taking an
ethically responsible decision to offer personalized nutri-
tion advice based upon gene–diet–health interaction.
According to the first position, the evidence base for
translating the outcomes of nutrigenomics research into
personalized nutritional advice is as yet immature. There is
also limited evidence that genotype-based dietary advice
will motivate appropriate behavior changes. Filling the
gaps in our knowledge will require larger and better ran-
domized controlled trials. According to the second posi-
tion, personalized nutrition must be evaluated in relation to
generally accepted standard dietary advice—partly derived
from epidemiological observations and usually not proven
by clinical trials. With personalized nutrition, we cannot
demand stronger evidence. In several specific cases of
gene–diet interaction, it may be more beneficial for indi-
viduals with specific genotypes to follow personalized
advice rather than general dietary recommendations. The
ethical comment, finally, considers the ethical aspects of
deciding how to proceed in the face of such uncertainty.
Two approaches for an ethically responsible way forward
are proposed. Arguing from a precautionary approach, it is
suggested that personalized dietary advice should be
offered only when there is strong scientific evidence for
health effects, followed by stepwise evaluation of unfore-
seen behavioral and psychological effects. Arguing from
theoretical and applied ethics as well as psychology, it is
also suggested that personalized advice should avoid
paternalism and instead focus on supporting the autono-
mous choice of each person.
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Introduction
Since the early days of nutritional genomics research, there
has been interest in the possibility of using the growing
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knowledge related to gene–diet interactions to provide
personalized dietary advice based on the individual geno-
type (Kaput and Raymond 2006). However, scientists have
debated when the timing would be appropriate for trans-
lating the outcomes of this research into public health
action. A major question in this respect is whether the
scientific evidence is sufficiently strong to offer personal-
ized nutritional advice based on genotypic information.
This article brings together three voices to discuss this
question from a scientific as well as an ethical perspective.
It is based on two contrasting scientific voices. The first of
them asks whether the science is strong enough and argues
that the evidence base for translating the outcomes of
nutrigenomics research into personalized nutritional advice
is immature. The second, on the other hand, asks: If not
now, when? The ethical comment, finally, considers the
ethical aspects of deciding how to proceed in the face of
such uncertainty. The article provides an ethical context for
the EU FP7 project Personalised nutrition: an integrated
analysis of opportunities and challenges, known as
Food4Me, which is attempting to provide empirical evi-
dence of the utility of a personalized approach to
nutritional advice.
Personalized nutrition: is the scientific evidence strong
enough?
Recent studies concerning the interactions between nutri-
tion and the genome have yielded promising results. They
have revealed much about the ways in which individual
genotypes modulate the responses to dietary factors and
have provided rich mechanistic insights into how nutrients
and other components of foods regulate gene expression as
well as cell and tissue functions (the science of nutrige-
nomics). In addition, technological advances have driven
down the costs and improved the reliability and availability
of personal genome testing (PGT). A recent survey of
public awareness of and interest in PGT in the United
Kingdom found that only 13 % of respondents knew about
PGT (Cherkas et al. 2010). However, once it had been
explained to them, 93 % of respondents claimed that they
would be interested in having a free PGT ‘‘to encourage
them to adopt a healthier lifestyle if found to be at high
genetic risk of a disease’’ (Cherkas et al. 2010). However,
other researchers have determined that low levels of
‘‘genetic literacy,’’ particularly among those most at risk of
common complex diseases, are a current barrier to the
communication of genotype-based risk information
(McBride et al. 2010).
There is compelling evidence that each individual’s
health is determined by interactions between his or her
fixed genotype and nutrition (and other environmental
exposures) together with the effects of stochastic events—a
hypothesis that is conceptualized in the ‘‘health pendulum’’
(Mathers 2002). This phenotypic plasticity is the mecha-
nistic basis on which lifestyle-based interventions aimed at
improving health and well-being can be developed. To
date, most nutritional interventions have been generic
(population level), with limited attempts to stratify or
personalize these interventions. Such personalization could
be achieved by consideration of each individual’s dietary,
phenotypic, or genotypic characteristics. Since behavior
change is key to any health improvement from dietary
interventions, the important question to be addressed is the
following: will personalized nutrition produce larger, more
appropriate, more sustained, more cost-effective behavior
change and greater gains in health and well-being than can
be achieved by conventional dietary advice? Focusing on
personalization using genotypic information, the major
questions include the following:
• Is our current understanding of diet–gene–health rela-
tionships sufficiently robust as a basis for offering
useful genotype-based dietary advice?
• If people are offered genotype-based dietary advice, are
they more likely to change their eating behavior in
more healthful ways? (see Bouwman 2009).
Assessment of our understanding of diet–gene–health
relationships
There is convincing evidence that the risk of common diet-
related diseases, such as cardiovascular disease (CVD),
type 2 diabetes, osteoporosis, dementia, and some cancers,
is influenced by genetic factors and that carrying specific
genetic variants can modulate individual biological
responses to nutrients. However, knowledge in this area is
fragmentary, and very few diet–gene–health relationships
have been tested for causality in human intervention
studies (Joost et al. 2007).
For example, higher intakes of oily fish (or fish oil) are
associated with lower risk of CVD through mechanisms
that may include lowering of plasma triacylglycerol (TAG)
concentrations by the long-chain polyunsaturated fatty
acids, eicosapentaenoic (EPA), and docosahexaenoic
(DHA). However, when people are given extra EPA and
DHA under controlled conditions, there is substantial inter-
individual heterogeneity in the TAG response, with some
individuals showing an increased, not decreased, TAG
concentration (Madden et al. 2011). To obtain proof-
of-principle that some of this inter-individual variation in
response is due to genotype, adult participants were pro-
spectively genotyped for apolipoprotein E (APOE) before
recruitment into a randomized controlled trial (RCT), in
which they were given two doses of fish oil (Caslake et al.
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2008). This demonstrated that both the APOE genotype and
gender determined the TAG response to fish oil supple-
mentation (Caslake et al. 2008).
The literature was comprehensively searched to establish
the strength of the evidence for the impact of genotype on the
fish oil–CVD risk relationship (Madden et al. 2011). This
review revealed the following: (1) there is a distinct lack of
information on the factors that determine inter-individual
responsiveness to fish oil; (2) few diet–gene–health rela-
tionships have been confirmed in independent studies; and
(3) there is a paucity of RCTs that used prospective geno-
typing. In addition, it was concluded that considering single
genes (and gene variants) may be too simplistic (Madden
et al. 2011). This and other studies demonstrate that though
diet–gene–health relationships are undoubtedly important,
they remain poorly understood (Joost et al. 2007).
Behavioral responses to genotype-based information
Limited empirical evidence addresses the question: ‘‘Will
people change their eating behavior in healthier ways if
they are offered genotype-based dietary advice?’’ A recent
systematic review investigated the effectiveness of DNA-
based advice in changing behavior with respect to diseases
for which risk could plausibly be reduced by behavioral
change. Only 14 papers were found, which reported the
results from seven clinical studies (two papers reported on
the same trial) and six analog studies, that is, studies in
which participants were asked to imagine their responses to
genotypic information (Marteau et al. 2010). Of these, just
two studies assessed the effects on dietary behavior.
The first study tested the hypothesis that disclosing
evidence of a genetic mutation in individuals with a clin-
ical diagnosis of familial hypercholesterolemia (FH) would
reduce the patient’s perception of control over the disease
and adherence to risk-reducing behavior, including dietary
behavior (Marteau et al. 2004). No mutation was discov-
ered in some study participants who acted as controls,
although the study inclusion criteria required that all par-
ticipants be patients who suffered from FH. Six months
later, compared with controls (no mutation discovered),
significantly (p\ 0.02) fewer participants who discovered
that they had a mutation believed that ‘‘eating a lower fat
diet would reduce my cholesterol level.’’(Marteau et al.
2004) In contrast, more participants who discovered that
they had a mutation believed that ‘‘taking medication
would reduce my cholesterol level’’ (p = 0.06) (Marteau
et al. 2004). In summary, genetic testing that confirmed the
diagnosis of FH seemed to weaken the participants’ belief
in the effectiveness of dietary change (Marteau et al. 2004).
The Risk Evaluation and Education for Alzheimer’s
Disease (REVEAL) study examined the impact of disclo-
sure of APOE e4 status on behavior change in the adult
offspring of parents with Alzheimer’s disease (AD) (Chao
et al. 2008). Because a parent suffered from the disease, all
study participants were at a higher-than-average AD risk
and carrying the APOE e4 variant added further to their AD
risk. All REVEAL participants were given a numerical
estimate of their AD risk; they were divided into three
groups—those who were not given any genotypic infor-
mation (controls) and those who were tested for APOE e4
and those who had their APOE e4 status communicated to
them (positive or negative). One year later, participants
were asked about changes in their behavior, including
changes in diet and exercise, that would be expected to
reduce AD risk (Chao et al. 2008). Similar proportions of
positive behavior changes were reported among controls
and among participants who told that they were APOE e4
negative. However, a positive behavior change was
reported approximately twice as often among participants
who told that they were APOE e4 positive (Chao et al.
2008). Nevertheless, this finding should not be interpreted
as unequivocal evidence that genotype-based evidence can
motivate positive behavior change. Participants who were
APOE e4 positive had received a higher overall numerical
AD risk score, and it is possible that it was the greater risk
score, as distinct from the genotypic information, that
enhanced the motivation for a behavior change (Fanshawe
et al. 2008).
Following a systematic review, Marteau et al. (2010)
drew attention to the weak evidence about the effects of
communicating DNA-based information on risk-reducing
behavior. They stated, ‘‘Claims that receiving DNA-based
test results motivates people to change their behavior are
not supported by the evidence,’’ and they called for larger
and better-quality RCTs (Marteau et al. 2010).
In summary, the evidence base for translating the out-
comes of nutrigenomics research into personalized nutri-
tional advice is immature. In addition to significant gaps in
the relevant basic science, there is limited evidence that
genotype-based dietary advice will motivate appropriate
behavior changes and that interventions based on such
advice will be more cost-effective than conventional pop-
ulation-level interventions (Hall et al. 2010). Filling these
gaps will require larger, better-designed RCTs.
Personalized nutrition: if not now, when?
It is sometimes asked whether personal genetics is ready
for ‘‘prime time’’ (Haga et al. 2003; Khoury 2010). If prime
time means that personal genetics should be broadly
adopted and reimbursed by insurance or public health
services, the answer is probably no. But that does not mean
that it is not ready at all: some specific gene–diet interac-
tions should probably be seriously considered by expert
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committees (see examples below for MTHFR and GST
genes); and there are others for which the evidence of
probable benefit is sufficient for it to be communicated by
scientists and health professionals to the public. The goal
of personalized nutrition is not to substitute the official
guidelines but to enhance or modify them for the individual
where there is available evidence to do so. This is not a
new development, but a practice that is old as the guide-
lines themselves: overweight people are advised to
consume fewer calories than the recommended intake;
lactose-intolerant individuals are advised to avoid or limit
their intake of fresh dairy products; now, we have the
opportunity to consider the evidence from gene–diet
interaction studies.
Nutrigenetics is part of a wider debate about personal
genetics, which began with the launch of Sciona Ltd. in the
United Kingdom in 2001 (Sciona 2001) and continued
following the launch of companies such as 23andMe,
deCode, and Navigenics in 2007. The overriding question
is about clinical utility—can the results of nutritional
genetics studies be translated into beneficial dietary advice
that would not be available without the use of genetic
information? To understand what may or may not be
possible, it is necessary to keep personalized nutrition in its
appropriate context and not to conflate it with clinical
genetics, disease prediction, or disease therapy. Nutrige-
netics does not use genetic information in the same way as
classical genetics does; it does not calculate disease risk
based on association studies (such as 23andme-type ser-
vices) but uses precise information based on specific gene–
diet interactions. Often, the genetic variants are functional,
which means that they have effects on proteins (such as
reduced enzyme activity or altered transporter levels) that
have been demonstrated to modify individual responses to
dietary components. This important distinction is often
overlooked: nutrigenetics operates at the level of genetic
influence on biological processes and is not required to
provide any information beyond metabolic information
(Paynter et al. 2010).
Healthy eating is not a straightforward proposition in the
modern world, and expert committees charged with the
responsibility of making dietary recommendations have to
do so in the context of complex and incomplete informa-
tion. To declare that it is too early to include genetics in
nutritional advice is not simply to adopt a wait-and-see
attitude: it is to actively recommend that normal healthy
people follow conventional nutritional guidelines based on
epidemiological and other evidence and set aside the evi-
dence for certain gene–diet interactions. The level of evi-
dence for genetically influenced nutritional advice should
be assessed according to the same standards as traditional
nutritional advice, but this does not often occur. Although
the evidence of gene–diet interactions is not denied by
experts, the question is this: is it of a sufficient level to be
used now? The apparently cautious ‘‘it’s too early’’
approach is to decide that the evidence in support of the
following generic daily recommendations (FSA 2007) is of
higher quality than any of the ‘‘genes and nutrition’’
evidence:
• 200 lg folic acid
• 40 mg vitamin C
• No more than 6 g salt
• At least five portions of a variety of fruit and vegetables
• No more than 11 % of energy from saturated fat
Some authors feel that until genetic-based advice has
been proven to be beneficial, the standard guidelines should
be followed, and often this means being proven by the gold
standard—the randomized clinical trial. Though some
studies have reported clinical benefits of lifestyle inter-
ventions in diseased or higher-risk individuals—for
example in preventing type 2 diabetes (Perreault et al.
2012)—no single element of the recommendations from
the Food Standards Agency (FSA) of the United Kingdom
has been proven by clinical trial to prevent or delay disease
in healthy people. The evidence for these recommendations
has been derived from epidemiological observations, small
intervention trials, and clinical trials of biomarkers. The
FSA recommends specific limits on salt and saturated fat
intake with the aim of preventing hypertension and an
imbalanced low-density/high-density lipoprotein profile,
which are risk factors for CVD, among others. The FSA
recommendations are ultimately, of course, aimed at dis-
ease prevention, but although lowering dietary salt and
saturated fats have positive effects on hypertension and
lipid profiles, as demonstrated in clinical trials of healthy
populations, there are no actual trial data that ‘‘prove’’ a
consequent reduction in disease of these dietary interven-
tions (Furberg 2012; Mitka 2012).
The lack of data on ultimate disease causality and pre-
vention should not be a surprise. Nutrition is highly com-
plex, and its effects on long-term health begin even before
birth. It is not possible to take a nutritional element in
isolation and test efficacy in disease prevention as if it were
a new drug or surgical procedure. The same is true for
nutrigenetics, which is sometimes wrongly held to a higher
standard than ordinary nutritional advice (e.g., Haga et al.
2003; Wood 2008); this results in disregarding high-quality
evidence for several gene–diet interactions. The most
widely studied is that between the MTHFR gene C677T
polymorphism, folic acid, and homocysteine. The follow-
ing has been reliably demonstrated (Homocysteine-
Lowering Trialists’ Collaboration 2005):
• The 677T version of the enzyme has only about 35 %
of the activity of the 677C version.
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• A low folate status leads to high homocysteine levels in
TT individuals. (For example 200 lg folic acid has
been shown in many trials to be insufficient to maintain
homocysteine levels below the risk level in this genetic
group.)
• It is accepted that increasing folate intake to
400–600 lg per day will keep homocysteine levels
below the risk level in most TT individuals.
• There is no reliable evidence of harm, and these levels
are well below the advised upper limits.
• Homocysteine is accepted as an independent risk factor
for cardiovascular and other diseases; though causality
has not been proven, the evidence is high (Wald et al.
2006).
For a healthcare practitioner, to reject this evidence is to
recommend that individuals with two copies of the slow
enzyme need only 200 lg folic acid per day regardless of
the fact that their homocysteine levels will be likely to
remain high for years or decades. It is to decide that
chronic high homocysteine is likely to be less harmful than
400–600 lg folic acid per day. Neither position has been
proven by clinical trial in healthy individuals to prevent or
delay disease, and it is not likely that such positions will be
proven since, apart from major compliance problems, such
a trial would require very large numbers of participants and
would last too many years. Over 10 homocysteine-lower-
ing trials have been carried out, and they are often cited by
way of refuting any benefit of homocysteine reduction in
primary prevention. However, these were all short-term
trials in older people already suffering from (mainly) CVD
and taking several medications, and they measured the
incidence of further cardiovascular events. None of the
trials were carried out on healthy people. The only possible
conclusion from these studies was that over the trial period,
there was no apparent benefit in lowering homocysteine in
ill people, i.e., secondary prevention. The results are
unlikely to be relevant to primary prevention, and there are
also good arguments why only tentative conclusions can be
drawn from these trials in any case (Wald et al. 2011).
Despite this the majority opinion in the clinical world is to
conclude that the ‘‘results do not support the use of folic
acid … as a preventive treatment’’ (Lonn et al. 2006), and
‘‘randomized trials of vitamin therapy with folate, vitamin
B6, vitamin B12 … demonstrated that none … are
effective for preventing cardiovascular disease … in the
general population’’ (Tice 2010).
In comparison, various salt-lowering trials had similar
negative results on disease prevention but the common
medical response is that since the RCTs were performed in
patients with existing heart disease, the results ‘‘… although
applicable to heart failure patients, lack public health rele-
vance: primary prevention’’ (Alderman 2010). This is
inconsistent. There are no fundamental differences in the
homocysteine- and salt-lowering trials, but the interpreta-
tions of the outcomes are radically different.
Another very well studied gene–diet interaction involves
cruciferous vegetables, which were shown to be associated
with reduced lung cancer in GSTT1- and GSTM1-null
individuals, but not in individuals who had working copies
of both genes (Brennan et al. 2005). Other authors have
demonstrated gene–diet-dependent effects on reduced
DNA damage (Palli et al. 2004), reduced prostate cancer
risk (Steinbrecher et al. 2010), and increased levels of GST
alpha (Lampe et al. 2000). These interactions among
genotype, cruciferous vegetables, and lung cancer risk have
also been confirmed in a systematic analysis (Lam et al.
2009). In a recent review (McCann et al. 2010), the authors
assessed the evidence and made the following statement:
It can be concluded from the majority of these anal-
yses that cruciferous vegetables are likely to play an
important role in cancer prevention, the strength of
which may be dependent to some extent upon expo-
sure to other carcinogens and genotypes for GSTs.
But with regard to their overall conclusion, they wrote
thus:
However, we do not believe that nutrigenetics is a
doorway to individualized genotyping for risk
assessment and dietary counseling … Finally, it
should be noted that regardless of one’s genotype a
balanced diet high in fruits, vegetables, and whole
grains and low in meat and fats may be beneficial for
overall health and well-being and prevention of
numerous diseases … the public health message of
consumption of a healthy diet should not be influ-
enced by knowledge of one’s genetic makeup.
This article is a review of several studies of gene–diet
interactions as well as those on GST and cruciferous veg-
etables, and not all the studies gave consistent results;
however, the intended meaning of the final sentence is not
completely clear. One interpretation is that having assessed
all the evidence, the authors believe that this evidence is
still not sufficiently reliable to allow GST gene–cruciferous
interactions to be incorporated into any sort of nutritional
advice communicated to the public. If this is the correct
interpretation, the next question is what level of evidence
would be sufficient to inform GST-null individuals about
the probable increased cancer protection provided by a
particular type of vegetable for carriers of their genotype?
In summary, the use of genotypic information in per-
sonalized nutrition has been subjected to some skepticism
for various reasons, including exaggerated health claims,
Genes Nutr (2013) 8:373–381 377
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mistaken interpretations, genuinely exploitative products,
and the difficulty of proving cause and effect (as in any
type of nutrition research). Nutrition research and candi-
date-gene association studies have produced many incon-
sistent results over the decades. This is not related to the
overall quality of the research, rather it is because of the
complexity of the effects of nutrition on long-term health.
The situation though is improving, as genotyping costs
have dramatically decreased, the increasing inclusion of
genetics in many nutritional studies over the last few years
has been one of the factors that has helped to bring more
clarity (Grimaldi 2010).
Nutrigenetics is part of the information that contributes
to personalized nutrition as a whole. Where there is sup-
porting evidence, it should be added to other phenotypic
information (such as health status, ethnicity, and gender),
and genetic evidence should be assessed at the same level
as phenotypic evidence. Preliminary studies suggest that
including genetic information may be useful in long-term
weight loss (Arkadianos et al. 2007), and a recent
randomized control trial reported that genotype-based
personalized dietary advice was better understood and
more likely to be followed than general dietary advice
(Nielsen and El-Sohemy 2012). There is good evidence of
some clinical and personal utility with respect to genotype-
based personalized nutrition, and this should be made more
widely available to allow individual decisions to be made.
Can ethics help to solve this problem?
Plea for a precautionary approach
A common ethical approach to situations where there is
doubt about the right choice of action is to suggest a cost–
benefit analysis. How can such an analysis be applied in the
case under discussion? Costs and benefits cannot be cal-
culated in general, but they must be estimated for a specific
action where the consequences may be foreseen. It is thus
evident that a cost–benefit analysis in the present case must
relate to an understanding of the specific consequences of
gene–nutrition or lifestyle–nutrition interaction and spe-
cific nutritional advice that may influence such
consequences.
In many cases, we have no or only limited knowledge of
the consequences of alternative actions. The precautionary
principle has often been used in handling such situations.
However, this principle is understood in many ways; it has
been widely discussed, and its usefulness has been ques-
tioned. Can it be helpful as a tool in personalizing nutri-
tion? A common and basic understanding of the principle is
that we should exercise caution in avoiding actions where
we cannot foresee the risks. However, when the risks are
unknown, it is difficult to apply the notion of risk avoid-
ance. How can we avoid unknown risks? With this prob-
lem, it has been suggested that it is useful to distinguish
between three different situations: (1) where the risk level
is well known; (2) where there is uncertainty about the
level and character of the risks involved; and (3) ignorance,
where the risks are unknown (COMEST 2005).
It has rightly been argued that in the case of ignorance,
precautions are irrelevant. We cannot know whether
something is safe or not without some experience of risk
levels (Wildavsky 1988). Wildavsky argues that in the case
of ignorance, small-risk taking, followed by stepwise
evaluation, is a safer course than avoiding risk.
One interpretation of the precautionary principle that
may be useful here concerns prudent housekeeping
(Boehmer-Christiansen 1994). In good housekeeping bud-
geting, predictions have a certain range of uncertainty. It is
then a good strategy to underestimate income and other
benefits and overestimate expenses and risks within the
relevant range of uncertainty. The result will be a cautious
estimation of the balance between benefits and risks, and it
will also allow steps to be taken to modify that balance by
increasing the benefits and diminishing the risks as
appropriate. In this interpretation, it is reasonable to
understand the precautionary principle as a complement to,
rather than a substitute for, cost–benefit analysis (Dana
2003).
The recipient understands personalized nutritional
advice as being a prediction (based on probability and
limited knowledge) that the recipient who follows this
advice has a better chance of improving their health rather
than following general advice about healthy eating. The
short history of personalized nutrition indicates that the
advice offered has often been questionable either because
the knowledge base was too limited or because the advice
promised too much or was difficult to understand or apply.
The articles that follow in this section of the special issue
examine further details related to this discussion.
The above considerations show that to date nutrige-
nomics has been able not only to create expectations, but
also to offer important pieces of new knowledge; however,
our understanding of the whole picture of diet–gene
interactions is still fragmentary. For example, knowledge is
limited about the interactions among different genes and
about the net effects on health outcome of multiple gene
variants interacting with nutrition. There is good evidence
that diet (and other lifestyle exposures) has an impact on
epigenetic factors, though how this impact affects health
remains poorly understood (Mathers et al. 2010). In addi-
tion, the important step from knowledge about a diet–gene
interaction to the development of clear advice on changes
in nutritional intake or other behavioral change has proven
complex. The precautionary introduction of variables to be
378 Genes Nutr (2013) 8:373–381
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used for personalized dietary advice calls for a careful
selection of single nucleotide polymorphisms, biomarkers,
or other factors with sufficiently strong evidence that
appropriate behavioral change is likely to produce positive
health effects.
Much remains to be elucidated about the importance of
food for well-being in a wide sense and about individual
responses to tailor-made dietary advice, and this lack of
knowledge creates a complex ethical situation (Görman
2006). This lack also makes it important to observe care-
fully behavioral responses to the outcomes of personal
genome testing and of personalized dietary advice based on
genotypic information. It may be appropriate to undertake
such monitoring initially with only a limited amount of
advice, followed by a stepwise evaluation of increasingly
complex advice. A precautionary approach should there-
fore involve adjusting the advice to account for unforeseen
behavioral and psychological effects.
Plea for respect for autonomy
Such estimations as risk–benefit analyses are carried out by
such experts as scientists, medical doctors, or other
authorities for the benefit of the recipients of the medical
advice. To give advice based upon these analyses may thus
be perceived as a way of telling people what they ought to
do. This may involve a certain amount of paternalism,
expressing an attitude of superiority over others. From an
ethical point of view, this is a theoretically interesting, but
also a questionable, way of dealing with a situation where
advice is given to others to support them in improving their
lives. A great many efforts in ethics as well as applied
psychology aim at suggesting alternative approaches.
Three examples can illustrate this point.
In the sphere of ethical politics, value-driven documents
related to interventions in the health field strongly point out
the respect for the integrity, freedom, and dignity of all
human beings as a central value. One influential example is
the Convention on Human Rights and Biomedicine, issued
by the Council of Europe. The explanatory report of this
convention makes it clear that paternalism may come in
conflict with the above value and that one ambition of the
convention is to restrain paternalist approaches (Council of
Europe 1997).
In ethical theory, similar questions are often brought up
by means of the concept of autonomy, that is, the capacity
to be one’s own person. In the influential moral psychology
of Immanuel Kant motivation, individual freedom, and
autonomy belong closely together. Kant understood indi-
vidual freedom as a situation where a person is bound only
by their own will, not by the will of someone else. Such
freedom is crucial for individual autonomy (Kant 2003;
Schneewind 1998). In modern medical ethics, respect for
individual autonomy, understood as the right of each per-
son to decide by themselves, is commonly considered an
important value (Beauchamp and Childress 2008).
In psychology, the influential ideas of Carl Rogers and
his followers are based upon the understanding of the
individual human being as a self-structuring value-driven
organism. The person-centered therapy derived from his
theories is focused on finding and mirroring this capacity in
the individual instead of trying to impose the thoughts of
others. As Rogers wrote, ‘‘A person cannot teach another
person directly; a person can only facilitate another’s
learning’’ (Rogers 1951). Today, person-centered therapy
is a widely used approach in psychotherapy, often descri-
bed as characterized by genuineness, unconditional posi-
tive regard, and empathetic understanding. Several studies
indicate that a person-centered approach to behavioral
change is efficient and beneficial (Cooper et al. 2010).
With respect to personalization of nutrition, it is evident
that such values as integrity and autonomy are relevant
since the goal of dietary advice is a change in lifestyle.
These values may be respected by developing methods for
nutritional advice that focus on supporting the autonomous
choice of each person. Advice can help in understanding
the causality and benefits of adjusting lifestyle and nutri-
tion to individual properties. However, the person who
receives the advice is the only one who can integrate such a
choice within their personal value system. The significance
of autonomy, trust, and trustworthiness dealt with in this
article is further discussed in the following articles in this
special issue.
Conclusion
There is convincing evidence that common diet-related
diseases are influenced by genetic factors, but knowledge
in this area is fragmentary and few relationships have been
tested for causality. The evidence that genotype-based
dietary advice will motivate appropriate behavior changes
is also limited. However, traditional nutritional advice is
not always based upon causality but also on observational
epidemiological studies. In several specific cases of gene–
diet interaction, it may be more beneficial for identifiable
groups of individuals with specific genotypes to follow
personalized nutritional advice rather than general dietary
recommendations. From an ethical perspective, a precau-
tionary approach is to be recommended, where personal-
ized dietary advice is offered only for variables with
sufficiently strong evidence for health effects, followed by
a stepwise evaluation of unforeseen behavioral and psy-
chological effects. When offering such advice, paternalism
should be restrained, and the focus should be on supporting
the autonomous choice of each individual.
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